Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ATP1A1 | P05023 | 10/20 | 0.43 |
| ▸ | ATP1B1 | P05026 | 10/20 | 0.43 |
| ▸ | ATP1A3 | P13637 | 10/20 | 0.43 |
| ▸ | ATP1B2 | P14415 | 10/20 | 0.43 |
| ▸ | ATP1A2 | P50993 | 10/20 | 0.43 |
| ▸ | ATP1B3 | P54709 | 10/20 | 0.43 |
| ▸ | FXYD2 | P54710 | 10/20 | 0.43 |
| ▸ | ATP1A4 | Q13733 | 10/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22692182 | 0.93 | LMNA (0.45) | LMNASMN1; SMN2MAPTTP53GAA | |
| SCHEMBL20046484 | 0.89 | LMNA (0.44) | LMNASMN1; SMN2MAPTTP53GAA | |
| SCHEMBL23483078 | 0.86 | MAPT (0.50) | LMNASMN1; SMN2MAPTTP53GAA | |
| SCHEMBL23483079 | 0.86 | MAPT (0.42) | LMNASMN1; SMN2MAPTTP53GAA | |
| SCHEMBL20075874 | 0.85 | MAPT (0.40) | LMNASMN1; SMN2MAPTTP53GAA | |
| SCHEMBL22964377 | 0.83 | TP53 (0.53) | LMNASMN1; SMN2MAPTTP53GAA | |
| SCHEMBL24197722 | 0.83 | GAA (0.50) | LMNASMN1; SMN2TP53GAAUSP2 | |
| SCHEMBL22964379 | 0.81 | LMNA (0.38) | LMNASMN1; SMN2MAPTTP53GAA | |
| SCHEMBL22692335 | 0.81 | LMNA (0.37) | LMNASMN1; SMN2MAPTTP53GAA | |
| SCHEMBL20046815 | 0.81 | MAPT (0.39) | LMNASMN1; SMN2MAPTTP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| EP-3971176-A1 | AROMATIC AMINE AR AND BET TARGETING PROTEIN DEGRADATION CHIMERA COMPOUND AND USE | Hinova Pharmaceuticals Inc. (CN) | 2022-03-23 | — | — | EP | disclosed |
| US-11236051-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210171470-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210040044-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-02-11 | — | — | US | disclosed |
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-01-14 | — | — | US | disclosed |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | LMNA 2916/4885SMN1; SMN2 3928/4885MAPT 2938/4885 |
| US-20210040044-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | LMNA 2932/4885SMN1; SMN2 3936/4885MAPT 2970/4885 |
| US-20210171470-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | LMNA 2932/4885SMN1; SMN2 3936/4885MAPT 2970/4885 |
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | LMNA 2916/4885SMN1; SMN2 3928/4885MAPT 2938/4885 |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | LMNA 2932/4885SMN1; SMN2 3936/4885MAPT 2970/4885 |
| US-11236051-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | LMNA 2916/4885SMN1; SMN2 3928/4885MAPT 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.